Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors
Status: | Completed |
---|---|
Conditions: | Lung Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - 70 |
Updated: | 7/1/2016 |
Start Date: | October 1993 |
End Date: | June 2015 |
Phase II Study of Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors
1. To determine the outcome of patients with potentially resectable superior sulcus tumors
of non-small cell histology treated by surgery followed by accelerated radiation
therapy and chemotherapy.
2. To evaluate toxicity, the initial local-regional control rate, sites of and time to
local and distant failures.
of non-small cell histology treated by surgery followed by accelerated radiation
therapy and chemotherapy.
2. To evaluate toxicity, the initial local-regional control rate, sites of and time to
local and distant failures.
Eligible (surgically resectable and medically operable) patients will have surgery followed
by radiation therapy, given twice daily, for 5 weeks if margins are negative and for 5-1/2
weeks for positive margins. Grossly positive margins can be treated by brachytherapy
followed by external radiotherapy.
Concomitant chemotherapy consisting of cisplatin given intravenously on days 1 and 8, and
etoposide taken by mouth 30-60 minutes prior to each radiotherapy treatment x the first 10
days. The cycle will be repeated start day 29.
If the patients are considered to have no evidence of disease in one month after completion
of chemotherapy, optional prophylactic radiotherapy to the brain will be give in 10
fractions once daily for 2 weeks.
by radiation therapy, given twice daily, for 5 weeks if margins are negative and for 5-1/2
weeks for positive margins. Grossly positive margins can be treated by brachytherapy
followed by external radiotherapy.
Concomitant chemotherapy consisting of cisplatin given intravenously on days 1 and 8, and
etoposide taken by mouth 30-60 minutes prior to each radiotherapy treatment x the first 10
days. The cycle will be repeated start day 29.
If the patients are considered to have no evidence of disease in one month after completion
of chemotherapy, optional prophylactic radiotherapy to the brain will be give in 10
fractions once daily for 2 weeks.
Inclusion Criteria:
1. No previous treatment.
2. Tumor must be resectable.
3. >/= 18 and = 70 years of age.
4. Zubrod performance status = or higher performance status if based only on pain.
5. Must have adequate bone marrow, liver and renal function as defined in 3.6.
Exclusion Criteria:
1. Cytological or histological proof of N3 disease.
2. Evidence of metastatic disease to distant sites.
3. Patients with impending cord compression will be ineligible.
We found this trial at
1
site
1515 Holcombe Blvd
Houston, Texas 77030
Houston, Texas 77030
713-792-2121

University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
Click here to add this to my saved trials
